Johnson & Johnson Stock (NYSE:JNJ)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$241.00

52W Range

$151.01 - $251.71

50D Avg

$230.34

200D Avg

$216.95

Market Cap

$589.48B

Avg Vol (3M)

$7.94M

Beta

0.26

Div Yield

$5.24 (2.14%)

JNJ Company Profile


Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Show More

Industry

Drug Manufacturers - General

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

136,967

IPO Date

Jan 02, 1962

Website

JNJ Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 25Dec 24Dec 23
Innovative Medicine$60.40B$56.96B-
MedTech$33.79B$31.86B$30.40B
INNOVATIVE MEDICINE--$54.76B

Fiscal year ends in Dec 25 | Currency in USD

JNJ Financial Summary


Dec 25Dec 24Dec 23
Revenue$94.19B$88.82B$85.16B
Operating Income$25.60B$22.15B$23.41B
Net Income$26.80B$14.07B$35.15B
EBITDA$32.58B$24.78B$23.32B
Basic EPS$11.03$5.84$13.88
Diluted EPS$11.03$5.79$13.72

Fiscal year ends in Dec 25 | Currency in USD

Latest Earnings Call Transcripts


Q1 26Apr 14, 26 | 12:00 AM
Q4 25Jan 21, 26 | 12:00 AM
Q3 25Oct 14, 25 | 8:30 AM

Peer Comparison


TickerCompany
AZNAstraZeneca PLC
NVSNovartis AG
NVONovo Nordisk A/S
GILDGilead Sciences, Inc.
UNHUnitedHealth Group Incorporated
ABBVAbbVie Inc.
MRKMerck & Co., Inc.
AMGNAmgen Inc.
PFEPfizer Inc.
SNYSanofi